Inify Laboratories
Claes Lindh is the Chief Medical Officer at Inify Laboratories, with a background in medicine and education from Karolinska Institutet. Prior to their current role, Claes Lindh served as an MD and Teacher at Karolinska Institutet, as well as an MD at Karolinska University Hospital. Lindh holds a Doctor of Philosophy (PhD) and a Doctor of Medicine (MD) from Karolinska Institutet.
Inify Laboratories
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.